GLP1R and diabetes mellitus: Since the approval of semaglutide by the United States Food and Drug Administration for chronic weight management, the rise in popularity of its class of diabetes medications has been fast and widespread.1 Patients and physicians are both learning of various benefits and off-label indications for this group of medications, referred to as glucagon-like peptide-1 receptor agonists (GLP-1 RAs).